Welcome to LookChem.com Sign In|Join Free

CAS

  • or

196205-20-6

6-Benzothiazolamine,7-methyl-(9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

196205-20-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 196205-20-6 Structure

  • Basic information

    1. Product Name: 6-Benzothiazolamine,7-methyl-(9CI)
    2. Synonyms: 6-Benzothiazolamine,7-methyl-(9CI);7-Methyl-1,3-benzothiazol-6-amine
    3. CAS NO:196205-20-6
    4. Molecular Formula: C8H8N2S
    5. Molecular Weight: 164.23
    6. EINECS: N/A
    7. Product Categories: BENZOTHIAZOLE
    8. Mol File: 196205-20-6.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 6-Benzothiazolamine,7-methyl-(9CI)(CAS DataBase Reference)
    10. NIST Chemistry Reference: 6-Benzothiazolamine,7-methyl-(9CI)(196205-20-6)
    11. EPA Substance Registry System: 6-Benzothiazolamine,7-methyl-(9CI)(196205-20-6)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 196205-20-6(Hazardous Substances Data)

196205-20-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 196205-20-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,2,0 and 5 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 196205-20:
(8*1)+(7*9)+(6*6)+(5*2)+(4*0)+(3*5)+(2*2)+(1*0)=136
136 % 10 = 6
So 196205-20-6 is a valid CAS Registry Number.

196205-20-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 7-methyl-1,3-benzothiazol-6-amine

1.2 Other means of identification

Product number -
Other names 6-Benzothiazolamine,7-methyl-(9CI)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:196205-20-6 SDS

196205-20-6Downstream Products

196205-20-6Relevant articles and documents

METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF

-

, (2008/06/13)

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

-

, (2008/06/13)

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

5- AND 6-(2-IMIDAZOLIN-2-YLAMINO) AND -(2-THIAZOLIN-2-YLAMINO)-BENZOTHIAZOLES AS ALPHA-2 ADRENERGIC LIGANDS

-

, (2008/06/13)

This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 196205-20-6